Relationship of BRCA1 and BRCA2 mutations with cancer burden in the family and tumor incidence

被引:0
|
作者
Eva Esteban Cardeñosa
Pascual Bolufer Gilabert
Inmaculada de Juan Jiménez
Sarai Palanca Suela
Eva Barragán González
Virginia González Anguix
Enrique Lerma Alejos
Isabel Chirivella González
Ángel Segura Huerta
Carmen Guillén Ponce
Eduardo Martínez de Dueñas
Dolores Cuevas Cuerda
Dolores Salas Trejo
机构
[1] University Hospital La Fe,Laboratory of Molecular Biology. Service of Clinical Analysis
[2] Hospital Clínico Universitario,Unit of Genetic Counselling in Cancer
[3] Hospital Universitario La Fe,Unit of Genetic Counselling in Cancer
[4] Hospital General de Elche,Unit of Genetic Counselling in Cancer
[5] Consorcio Hospital Provincial,Unit of Genetic Counselling in Cancer
[6] Health Agency of Valencia,Service of Protocolization and Assistance Integration, Healthcare General Directorate
[7] Consellería de Sanitat,Cancer Plan Office, Department of Public Health
来源
Familial Cancer | 2010年 / 9卷
关键词
Breast cancer; Ovarian cancer; /; mutations; Family selection criteria; Tumor incidence;
D O I
暂无
中图分类号
学科分类号
摘要
The aim of the present study is to analyze the relationship of the incidence of mutations in the two major genes BRCA1 and BRCA2 conferring risk of breast cancer (BC) and ovarian cancer (OC) with the cancer burden in families and with the presence and age of onset of BC/OC. We included 704 index patients (IP) and 668 family members of the IP who tested positive for BRCA1/BRCA2 who were studied in the Program of Genetic Counselling in Cancer of the Valencia Community (Spain). We found 129 IPs with deleterious mutations (18.3%), 59 in BRCA1 and 70 in BRCA2, detecting 396 mutations in this kindred. The incidence of mutations and their distribution between BRCA1 and BRCA2 showed a significantly uneven incidence among the family groups (P < 0.001). We found 179 tumors in the 396 mutation carriers (45%) and detected only 11 cancers among the 272 non-mutation carriers (P < 0.001). No differences in the tumor prevalence or the age of onset of cancer between the genes among the mutation carriers were found. The mutation carriers showed a 50% probability of having BC/OC at a median age of 49 years (95% CI 46–52 years) and 78% at the age of 70 years (95% CI: 71–85%). In conclusion the family burden of BC and OC is strongly associated with the incidence of BRCAs mutations and could foretell which of the two BRCAs genes is more likely to have mutations. Mutation carriers have a 50% risk of having BC/OC by the age of 50 years.
引用
收藏
页码:291 / 295
页数:4
相关论文
共 50 条
  • [31] The Role of Testing for BRCA1 and BRCA2 Mutations in Cancer Prevention
    McCarthy, Anne Marie
    Armstrong, Katrina
    JAMA INTERNAL MEDICINE, 2014, 174 (07) : 1023 - 1024
  • [32] Contribution of the BRCA1 and BRCA2 mutations to breast cancer in Tunisia
    Troudi, Wafa
    Uhrhammer, N.
    Sibille, C.
    Dahan, C.
    Mahfoudh, W.
    Souissi, C. Bouchlaka
    Jalabert, T.
    Chouchane, L.
    Bignon, Y. J.
    Ben Ayed, F.
    Elgaaied, A. Ben Ammar
    JOURNAL OF HUMAN GENETICS, 2007, 52 (11) : 915 - 920
  • [33] Assessing the Significance of BRCA1 and BRCA2 Mutations in Pancreatic Cancer
    Carnevale, Julia
    Ashworth, Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (28) : 3080 - +
  • [34] Screening for ovarian cancer in BRCA1/BRCA2 mutations carriers
    Synowiec, Agnieszka
    Wcislo, Gabriel
    Bodnar, Lubomir
    Gasowska-Bodnar, Agnieszka
    Szczylik, Cezary
    GINEKOLOGIA POLSKA, 2014, 85 (05) : 377 - 381
  • [35] The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers
    Iqbal, J.
    Ragone, A.
    Lubinski, J.
    Lynch, H. T.
    Moller, P.
    Ghadirian, P.
    Foulkes, W. D.
    Armel, S.
    Eisen, A.
    Neuhausen, S. L.
    Senter, L.
    Singer, C. F.
    Ainsworth, P.
    Kim-Sing, C.
    Tung, N.
    Friedman, E.
    Llacuachaqui, M.
    Ping, S.
    Narod, S. A.
    BRITISH JOURNAL OF CANCER, 2012, 107 (12) : 2005 - 2009
  • [36] The incidence of pancreatic cancer in women with a BRCA1 or BRCA2 mutation
    Katona, Bryson W.
    Lubinski, Jan
    Pal, Tuya
    Huzarski, Tomasz
    Foulkes, William D.
    Moller, Pal
    Eisen, Andrea
    Armel, Susan Randall
    Neuhausen, Susan L.
    Raj, Rebecca
    Aeilts, Amber
    Singer, Christian F.
    Bordeleau, Louise
    Karlan, Beth
    Olopade, Olufunmilayo
    Tung, Nadine
    Zakalik, Dana
    Kotsopoulos, Joanne
    Fruscio, Robert
    Eng, Charis
    Sun, Ping
    Narod, Steven A.
    CANCER, 2025, 131 (01)
  • [37] The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers
    J Iqbal
    A Ragone
    J Lubinski
    H T Lynch
    P Moller
    P Ghadirian
    W D Foulkes
    S Armel
    A Eisen
    S L Neuhausen
    L Senter
    C F Singer
    P Ainsworth
    C Kim-Sing
    N Tung
    E Friedman
    M Llacuachaqui
    S Ping
    S A Narod
    British Journal of Cancer, 2012, 107 : 2005 - 2009
  • [38] Screening for Genetic Mutations in BRCA1 and BRCA2
    Narod, Steven
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2015, 22 (12): : 1365 - 1365
  • [39] Oophorectomy in women with BRCA1 or BRCA2 mutations
    Burki, Talha Khan
    LANCET ONCOLOGY, 2014, 15 (04): : E156 - E156
  • [40] Founder mutations in BRCA1 and BRCA2 genes
    Ferla, R.
    Calo, V.
    Cascio, S.
    Rinaldi, G.
    Badalamenti, G.
    Carreca, I.
    Surmacz, E.
    Coliucci, G.
    Bazan, V.
    Russo, A.
    ANNALS OF ONCOLOGY, 2007, 18 : 93 - 98